Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications - Scorecard - MDSpire

Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications

  • By

  • Yong Zhang

  • Ting Wang

  • An-Qi Lyu

  • Fang Zhang

  • Fang-Hui Li

  • Ling-Di Zhao

  • Zi-Bing Wang

  • Yi-Man Shang

  • Bao-Zhen Ma

  • Xiao-Qun Dong

  • Quan-Li Gao

  • April 21, 2026

  • 0 min

Share

Clinical Scorecard: Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingSingle-center, phase II clinical trial (single-arm design)

Key Highlights

  • ORR

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Imaging assessments every 6 weeks for the first 12 cycles, then every 9 weeks
      • Safety assessments throughout the study, including specific adverse event monitoring

      Risks

        Patient & Prescribing Data

        Combination therapy may provide disease control despite low ORR; further investigation needed.

        Clinical Best Practices

        • recommendations

        References

        Original Source(s)

        Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications

        • by Yong Zhang, Ting Wang, An-Qi Lyu, Fang Zhang, Fang-Hui Li, Ling-Di Zhao, Zi-Bing Wang, Yi-Man Shang, Bao-Zhen Ma, Xiao-Qun Dong, Quan-Li Gao

        • April 21, 2026

        Related Content

        AI Tool Funded by NIH Estimates Cancer Prognosis Using Single-Cell Tumor Analysis

        • April 21, 2026

        What Causes Metastasis in Deadly Eye Cancer?

        Gene expression profiling sheds new light on malignant transformation in uveal melanoma

        • January 12, 2026

        • 3 min
        FLASH Radiotherapy Maintains Systemic and Tissue Balance While Effectively Targeting Tumors